Orexo announces positive data from phase 1 clinical study for OX640 - a nasal epinephrine rescue medication for allergic reactions
All four investigational formulations of OX640 were extensively absorbed and rapidly achieved clinically relevant plasma levels of epinephrine Data available today indicates significantly improved
United States Uppsala Lan Lena Wange Ir Communications Orexo Nasal Administration Nasdaq Stockholm Mid Cap
Source: finanznachrichten.de